GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » 6-1 Month Momentum %

Extrawell Pharmaceutical Holdings (HKSE:00858) 6-1 Month Momentum % : -21.05% (As of May. 26, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-26), Extrawell Pharmaceutical Holdings's 6-1 Month Momentum % is -21.05%.

The industry rank for Extrawell Pharmaceutical Holdings's 6-1 Month Momentum % or its related term are showing as below:

HKSE:00858's 6-1 Month Momentum % is ranked worse than
72.72% of 1118 companies
in the Drug Manufacturers industry
Industry Median: -4.16 vs HKSE:00858: -21.05

Competitive Comparison of Extrawell Pharmaceutical Holdings's 6-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extrawell Pharmaceutical Holdings's 6-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's 6-1 Month Momentum % falls into.



Extrawell Pharmaceutical Holdings  (HKSE:00858) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Extrawell Pharmaceutical Holdings  (HKSE:00858) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Extrawell Pharmaceutical Holdings 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Traded in Other Exchanges
N/A
Address
979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.
Executives
Mao Yumin 2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited 2201 Interest of corporation controlled by you
Ease Gold Investments Limited 2201 Interest of corporation controlled by you
Jnj Investments Ltd 2201 Interest of corporation controlled by you
United Gene Group Ltd 2201 Interest of corporation controlled by you
United Gene Holdings Limited 2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited 2101 Beneficial owner
Xie Yi 2201 Interest of corporation controlled by you
Huang Zhenping 2101 Beneficial owner
United Gene Industry Group Limited 2101 Beneficial owner
Chen Xuhua 2202 Interest of your spouse
Cheng Yong 2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines